Takatsuki, Japan

Katsuichi Shimoji


Average Co-Inventor Count = 4.2

ph-index = 4

Forward Citations = 52(Granted Patents)


Location History:

  • Takatsuki, JA (1978)
  • Takatsuki, JP (1979 - 1983)
  • Kyoto, JP (1990)

Company Filing History:


Years Active: 1978-1990

Loading Chart...
8 patents (USPTO):Explore Patents

Title: Katsuichi Shimoji: Innovator in Pharmaceutical Chemistry

Introduction

Katsuichi Shimoji is a prominent inventor based in Takatsuki, Japan. He has made significant contributions to the field of pharmaceutical chemistry, particularly in the development of compounds that enhance cellular immunity and possess anti-tumor properties. With a total of 8 patents to his name, Shimoji's work continues to impact the medical community.

Latest Patents

One of Shimoji's latest patents involves glucopyranose derivatives. This invention relates to glucopyranose compounds that enhance cellular immunity, making them useful as anti-tumor agents. Another notable patent focuses on prostaglandin 12 analogues and their pharmaceutical compositions. These new compounds exhibit pharmacological properties typical of prostaglandins and are more stable than existing options.

Career Highlights

Katsuichi Shimoji is currently associated with Ono Pharmaceutical Co., Ltd., where he applies his expertise in pharmaceutical research and development. His innovative work has led to advancements in drug formulations that can potentially improve patient outcomes.

Collaborations

Shimoji has collaborated with notable colleagues in his field, including Masaki Hayashi and Yoshinobu Arai. These partnerships have fostered a collaborative environment that encourages the exchange of ideas and innovation.

Conclusion

Katsuichi Shimoji's contributions to pharmaceutical chemistry through his patents and collaborations highlight his role as a key innovator in the industry. His work continues to pave the way for advancements in medical treatments and therapies.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…